» Articles » PMID: 36210881

Evaluation of Immune System in Patients with Transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A Descriptive Cross-sectional Study

Overview
Journal Health Sci Rep
Specialty General Medicine
Date 2022 Oct 10
PMID 36210881
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Thalassemia syndromes are the most common hemoglobinopathy globally related to blood transfusion and iron overload in the body. Splenectomy, excessive iron overload, and repeated exposure to antigens in blood transfusions can cause severe damage to the patient's immune system making the patient prone to frequent infection. This study evaluates the immune system status and infection rate in beta-thalassemia major patients receiving iron chelators.

Methods: This descriptive cross-sectional study was performed in Rasoul-e-Akram Hospital on patients with a beta-thalassemia major who had iron overload due to frequent blood transfusions. The percentage of lymphocyte markers was determined by flow cytometry. Serum levels of immunoglobin were measured by nephelometric assay. Also, Nitro blue tetrazolium and dihydrorhodamine assays were used to evaluate the phagocytic function.

Results: Of the 106 patients participating in this study, 59 (55.7%) and 47 (44.3%) are male and female, respectively. The mean age ± SD of participants was 24.7 ± 12.1 years with 4 to 55 years. There was no significant correlation between sex, the C3 and C4 complements, the lymphocyte markers, and the immunoglobulin levels. Furthermore, all of these variables increased significantly over 30 ( < 0.05). Moreover, there was a strong positive correlation between splenectomy and IgG immunoglobulin ( < 0.001) and CD16 ( = 0.005) lymphocyte marker.

Conclusion: Iron chelator agents effectively improve patients' immune system with thalassemia major. The increase in IgG and IgM immunoglobulins levels is due to frequent blood transfusions, which stimulate the immune system.

Citing Articles

Functional characterization of macrophages and change of Th1/Th2 balance in patients with pythiosis after Pythium insidiosum antigen immunotherapy.

Medhasi S, Sangphech N, Permpalung N, Torvorapanit P, Plongla R, Worasilchai N Sci Rep. 2024; 14(1):27363.

PMID: 39521871 PMC: 11550834. DOI: 10.1038/s41598-024-78756-x.


Neutrophil Diversity (Immature, Aged, and Low-Density Neutrophils) and Functional Plasticity: Possible Impacts of Iron Overload in β-Thalassemia.

Sae-Khow K, Charoensappakit A, Leelahavanichkul A Int J Mol Sci. 2024; 25(19).

PMID: 39408979 PMC: 11476590. DOI: 10.3390/ijms251910651.


Complications in patients with transfusion dependent thalassemia: A descriptive cross-sectional study.

Faranoush M, Faranoush P, Heydari I, Foroughi-Gilvaee M, Azarkeivan A, Parsai Kia A Health Sci Rep. 2023; 6(10):e1624.

PMID: 37841947 PMC: 10568004. DOI: 10.1002/hsr2.1624.


COVID-19 and β-thalassemia: in lieu of evidence and vague nexus.

Al-Kuraishy H, Ashour M, Saad H, El-Saber Batiha G Ann Hematol. 2023; 103(5):1423-1433.

PMID: 37405444 DOI: 10.1007/s00277-023-05346-8.


Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study.

Ehsanipour F, Faranoush P, Foroughi-Gilvaee M, Sadighnia N, Fallahpour M, Motamedi M Health Sci Rep. 2022; 5(6):e871.

PMID: 36210881 PMC: 9528955. DOI: 10.1002/hsr2.871.

References
1.
Taylor S, Shacks S, Qu Z, Wiley P . Type 2 cytokine serum levels in healthy sickle cell disease patients. J Natl Med Assoc. 1998; 89(11):753-7. PMC: 2608277. View

2.
Sen L, Goicoa M, Nualart P, Ballart I, Palacios F, Diez R . [Immunologic studies in thalassemia major]. Medicina (B Aires). 1989; 49(2):131-4. View

3.
Ehsanipour F, Faranoush P, Foroughi-Gilvaee M, Sadighnia N, Fallahpour M, Motamedi M . Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study. Health Sci Rep. 2022; 5(6):e871. PMC: 9528955. DOI: 10.1002/hsr2.871. View

4.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M, Del Vecchio G . Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10):1187-93. View

5.
Ricerca B, di Girolamo A, Rund D . Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis. 2011; 1(1):e2009028. PMC: 3033166. DOI: 10.4084/MJHID.2009.028. View